Royalty Report: Drugs, Cancer, Drug Discovery – Collection: 367305

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Cancer
  • Drug Discovery
  • Disease
  • Therapeutic
  • Biotechnology
  • cell therapy
  • Antibody
  • Delivery
  • Vaccine
  • Genome
  • Immune
  • DNA
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 367305

License Grant
Licensor grants an exclusive license, including the right to grant sublicenses, under the Licensed Patents and Licensed Technology to develop, make, have made, use, sell, offer for sale, and import Licensed Products in the Territory and in the Field of Use only.
License Property
Licensor owns one hundred percent interest in the Human Gene Therapy Research Institute located in Des Moines, Iowa.

Patent rights, proprietary information and know-how relate to our HyperAcute immunotherapy technology.

The patents include
Radioisotope concentrator methods and compositions;
Radiation enhanced gene therapy for treatment of tumors;
Differential inactivation of nucleic acids by chemical modification;
Herpes simplex virus amplicon mini-vector gene transfer system;
Methods and compositions for inducing complement destruction of tissue;
Human suppressor TRNA oligonucleotides and methods of use for same;
DNA Methylation associated with genetic instability in retroviral vector producing cells;
HSV-ATM Vector for ataxia-telangiectasia gene therapy;
Activation of ganciclovir for generating anti-tumor responses;
ATM Vector;
Dual adenoviral delivery of transgenes.

The inventions and Know-how include
Polyphosphokinase gene to attempt gene therapy by creating polymers of radioactive phosphate;
Sodium iodide symporter related efforts;
Improved Herpes simplex vectors;
Humanized T4 endonuclease V gene therapy for UV photoproduct damage;
Animal model of cancer in a(1,3)galactosyltransferase knockout mice.

Field of Use
HyperAcute immunotherapies are designed to break tolerance and enable longer duration of anti-tumor effect.  HyperAcute immunotherapy technology has a wide range of anti-cancer applications including two additional product candidates, HyperAcute Lung and HyperAcute Melanoma, in active clinical development.  HyperAcute immunotherapy technology is designed to fight cancer by activating the human body's naturally protective and rapid immune response to the a-Gal carbohydrate.  HyperAcute immunotherapy product candidates are composed of irradiated, live, allogeneic human cancer cells modified to express the gene that makes a-Gal epitopes. This exposure to a-Gal stimulates the human immune system to attack and destroy the immunotherapy cells on which a-Gal is present by activating complement, an important component of the immune system that is capable of cell destruction. After destruction, we believe the resulting cellular fragments bound by anti-a-Gal antibodies are processed by the immune system to elicit an enhanced multi-faceted immune response to tumor-associated antigens common to both the immunotherapy and the patient's tumor cells.

IPSCIO Record ID: 248290

License Grant
This amendment modifies the list of patents and adds sublicense clarifications. For clarity,  sales of Licensed Products by Licensee or its Affiliate to a Sublicensee for resale by such Sublicensee are not included in Net Sales,  sales of Licensed Products by a Sub licensee (including those Licensed Products purchased from Licensee or its Affiliates) to a Third Party that is not an Affiliate of such Sublicensee are included in Net Sales, and in the event that Licensee or an Affiliate of Licensee grants rights.
License Property
The amended list of patents include, but are not limited to Antitumor Vaccination Using Allogeneic Tumor Cells Expressing Alpha (1,3)-Galactosyltransferase;  Method for Tumor Treatment Using Infusion of Xenogeneic Cells to Induce Hyperacute Rejection and Innocent Bystander Effect;  Methods and Comp__ositions for Inducing Complement Destruction of Tissue;  and,  Herpes SimJ!lex Virus Amplicon Mini-Vector Gene Transfer System.
Field of Use
The patents are for cell therapies for tumor treatment.

IPSCIO Record ID: 415

License Grant
The Company acquired the intellectual property rights relating to certain combination immunogene therapy technology from Licensor, an individual.
License Property
The technology allows for making a tumor cell more recognizable by the immune system and rendering it susceptible to the cell-killing component of the immune response.

A patent application has been filed for the technology entitled Combination Immunogene Therapy, United States Patent Application No. 09/826,025.  The standard approach in utilizing gene therapy to combat cancer has been to attempt to replace defective genes in cancer cells, which has proven to be impractical because of the number of genes involved. The combination gene therapy technology invented by Dr. Chang uses GM-CSF (a granulocyte macrophage colony stimulating factor) and B7-2 (a T-cell co-stimulating factor) to both build the body’s immune system and destroy cancer cells.  The treatment involves injecting the patient with two genes in one virus carrying a combination of B7-2 and GM-CSF.  Our technology, which shows potential for fighting cancer by enhancing one’s immune system and thereby increasing the number of cells that naturally destroy cancer, has proven effective in eradicating experimental human brain tumors implanted in mice and has undergone Phase 1 clinical trials in Canada.

Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 372471

License Grant
Licensor grants a perpetual, non-terminable, worldwide, exclusive license, with the right to sublicense, under Licensed IP to Develop and Commercialize Licensed Products in the Field.

Licensor grants the co-exclusive, with Licensor and its Affiliates, worldwide, right and license in the Field, without the right to grant sublicenses, under Collaboration IP solely owned by Licensor and Licensors interest in jointly owned Collaboration IP, in each case solely to conduct research and Development under the Collaboration Plan as part of the Collaboration Program in accordance with the terms of this Agreement.

License Property
Licensor has developed and owns or has rights to certain Patents and technology relating to developing innovative gene therapies for genetic disorders;

Target Antigens will be defined to mean any and all oncology associated antigens, provided that from and after the third anniversary of the Effective Date of the Agreement.  Target Antigens will be limited to the oncology associated antigens designated.

T-Cell means any of the lymphocytes that mature in the thymus and have the ability to recognize specific peptide antigens presented by major histocompatibility complex antigens through the receptors on their cell surface.

Payload means peptide coding sequences. For clarity peptide coding sequences include peptide sequences encoding chimeric antigen receptor elements including targeting domain, spacer, transmembrane domains, cytoplasmic domains and other coding sequences.

CAR T-cell therapy represents a promising, emerging approach to treating cancer. Blood is withdrawn from a patient and the T-cells are then extracted from a patient's blood. These cells are then genetically modified to recognize and attack cancer cells and then re-introduced into the patient's blood. The patient’s genetically modified cells are intended to bind to and kill the target cancer cells.

Field of Use
The global strategic collaboration is to discover, develop and commercialize novel diseasealtering gene therapies in oncology.

The Field means the use of T-Cells expressing a CAR, with or without other engineering to enhance functionality and/or safety, including virus specific genetically modified T-Cells expressing a synthetic CAR, and T-Cells expressing native-virus antigen receptors or tumor-specific antigen receptors in which the T-Cells are genetically modified to enhance their performance, persistence or safety, in each case under for the treatment, modulation, palliation or prevention of cancer in humans.

The collaboration will focus on applying gene therapy technology to genetically modify a patients own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells.

IPSCIO Record ID: 227234

License Grant
Licensor hereby grants to Japanese Licensee an exclusive, royalty-bearing license under the Licensor Technology and Licensors interest in the Joint Technology, to make, have made use, sell and otherwise commercialize Collaboration Products for all uses in the Field in the Territory.
License Property
U.S. Patent Application Serial No. 08/745,375 entitled 'Methods for Promoting Wound Healing and Transplant-Assoctaed Vasculopathy'

U.S. Patent Application Serial No. 08/816,346 entitled 'Chimeric Adenoviral Coat Protein and Methods of Using Same'

U.S. Patent Application Serial No. 08/854,601 entitled 'Multigene HSV Vectors for Cancer Immunotherapy'

U.S. Patent Application Serial No. 08/861,773 entitled 'An Improved Method for the Production of Non-Group C Adenoviral Vectors'

U.S. Patent Application Serial No. 60/047,849 entitled 'Alternately Targeted Adenovirus'

U.S. Patent Application Serial No. 60/049,072 entitled 'Phage Vector and Methods of Use'

U.S. Patent Application Serial No. 60/054,329 entitled.'Targeted HSV Vectors'

Field of Use
Field shall mean Gene Therapy for the treatment of human cancer excluding any use of the vascular endothelial growth factor (VEGF) gene or tumor necrosis factor alpha (TNF) gene or, in each case, any portion or derivative thereof.

The collaboration involves the development of Ad.CD for immunotherapy of cancer based on the delivery of tumor antigen genes. Ad.CD, an adenovirus vector containing the cytosine deaminase ('CD') gene, is designed to convert a nontoxic precursor drug into fluorouracil to effect tumor destruction, either alone or in combination with radiation therapy.

IPSCIO Record ID: 26749

License Grant
The University hereby grants to Licensee, under the Licensed Patents and other intellectual property rights of The University, subject to all the terms and conditions of this Agreement, a non-transferable worldwide exclusive license for the term defined by Article III to make, have made, use, sell and practice the Invention.
License Property
The University has  produced an invention entitled Novel Vectors for Gene Delivery and Therapy (OCR 722) and Specific Vectors in Gene Delivery to HIV+ Cells (OCR 721) and Vectors for the Diagnosis and Treatment of Solid Tumors Including Melanoma, U.S. Patent Application no. 08/486,422 (the INVENTION).  This invention focuses on the design of vectors for specific delivery of genes to human immunodeficiency virus (HIV)-infected cells.
Field of Use
We have recently demonstrated that certain bacterial and protozoan organisms, e.g. Salmonella typhymurium, Leishmania amazonensis, and Mycobacterium avium exhibit invasion preference for human melanoma or colon carcinoma cells over normal human melanocytes and colon epithelium in culture.  Further, mutants of Salmonella typhymurium were isolated showing enhanced specificity for melanoma and colon carcinoma cells over that already shown by the wild type parental strain.  One such superinfective, tumor-specific mutant was further transfected with a Herpes simplex thymidine kinase gene that was able to convert the non-toxic prodrug, ganciclovir, to its toxic phosphorylated form when the Salmonella was infected into melanoma tumors, thus reducing the size of the tumors. The current invention uses similar technology to isolate mutants of Salmonella typhimurium or other suitable vectors that show specific invasion preference for HIV+ cells.  Once isolated, such mutants are subjected to further genetic modifications to express and secrete suicide gene products into the cytoplasm of the HIV+ cells.  Targets for the suicide gene products include both the HIV-infected cells and/or the AIDS virus itself.

IPSCIO Record ID: 263928

License Grant
With this amendment, the Parties revise and amend the Agreement to add the Collaboration Compound known as GI-6300 as a Drug Candidate under the Agreement and to remove the Collaboration Compound known as GI-10000 as a Drug Candidate under the Agreement.
License Property
GI-6300 means the series of Tarmogen products that express brachyury. GI-6301 is part of the GI-6300 series and means the single Tarmogen product that may become the subject of [an IND filing under CRADA #02264] and that expresses a human brachyury protein.
Field of Use
The focus of the compound in this agreement is for the treatment of cancer.

IPSCIO Record ID: 244658

License Grant
The Parties have an acquisition agreement.  Upon consummation of the Acquisition, the Parties desire to establish a new cooperative development program intended to discover, develop, and certify for use in humans one or more new pharmaceutical products.

Licensor grants an exclusive, worldwide license under the Ad Interferon-beta Product Licensor Patents and the Ad Interferon-beta Product Technology to develop, research, make, have made, use, have used, sell, offer for sale, import and have sold the Ad Interferon-beta Product in the Cancer Field and the Beta Interferon Field .

For the Manufacturing License,  Licensor will provide a transferable, limited license or subiicense as the case may be under the Licensor Technology and the Licensor Patents to manufacture such Clinical Vectors and Commercial Vectors to the extent necessary to enable Licensee to manufacture quantities of the Clinical Vectors and Commercial Vectors that otherwise would have been supplied by Licensor to Licensee under this Agreement, solely for use and application by Licensee for the uses and applications in the Territory that would be permitted under this Agreement with respect to such Clinical Vectors and Commercial Vectors purchased from Licensor.

Licensor grants a license, with right to grant sublicenses, under the Licensor Technology and the Licensor Patents to research, develop, manufacture, have manufactured, use, import, export, offer to sell or sell Products in the Territory.

Licensor grants  a nonexclusive, worldwide license, with right to sublicense to Contractors permitted under this Agreement,  to the Licensed Technology, other than the Applied Licensor Technology, as designated in the applicable Project Plan and Budget, and under any Licensor Patents, other than the Exhausted Licensed Patents and the Exempted Licensed Patents, as designated in the applicable Project Plan and Budget, which would, but for this license grant, be infringed by Licensees performance of its Development Tasks solely as necessary for performance of Licensees Development Tasks during and in the course of any approved Development Project.

In addition to the other rights granted under this Agreement, Licensor hereby grants an option to acquire a license, with the right to grant sublicenses, to Licensor Technology, that is not otherwise designated as Applied Licensor Technology in the applicable Project Plan and Budget, and under any and all Targeted Patents, that are not designated as Exhausted Licensor Patents or as Exempted Licensor Patents in the applicable Project Plan and Budget.

License Property
The patents include Adenovirus Vectors for Gene Therapy, and, .Method of Reducing an Immune Response to a Recombinant Adenovirus.

AAV Interferon-beta Product means a Product incorporating the Beta Interferon Gene and any AAV Vector as the delivery platform.

AAV Vector means an adeno-associated viral vector useful or potentially useful for the delivery of Genes to human cells.

Ad Interferon-beta Product means the Product incorporating the Beta Interferon Gene and an Ad Vector that is the subject of the Ad Interferon-beta Project.

Ad Vector means an adenoviral vector useful or potentially useful for the delivery of Genes to human cells.

Field of Use
Beta Interferon Field means the treatment or prevention in humans of one or more diseases through the use or application of one or more gene therapy vectors to deliver Genes; such Genes being defined herein as the Beta Interferon Genes.

Cancer Field means the treatment or prevention in humans of one or more cancers through the use or application of AAV Vectors or Ad Vectors.

IPSCIO Record ID: 222550

License Grant
Licensee desires Licensor to conduct research with the Mice to generate fully human monoclonal antibodies to certain Antigens.

For the Evaluation License, Licensor grants an exclusive, nontransferable license for the term of the applicable Evaluation Period to use the Collaboration Technology relating to such Antigen solely for the purpose of evaluating whether Licensee shall desire to acquire a commercial license to such Product(s) directed against such Antigen.

For the Option for Commercial Licenses, Licensee shall have an option to obtain a commercial license with respect to Product(s) directed against such Antigen in the Field of Use in all countries of the Territory,

For the Commercial License,  Licensor grants an exclusive, even as to Licensor, license, with the right to sublicense, under the Licensed Technology to make, have made, import, have imported, use, offer for sale and sell Product(s) directed against such Antigen in the Field of Use in the Territory.

For the Research License, Licensee shall have an irrevocable, perpetual, worldwide exclusive research license, without the right to sublicense, to make and use (but not to transfer, sell, lease, offer to sell or lease, or otherwise transfer title to or interest in the Antibody{ies) and Antibody Cell(s) transferred by Licensor to Licensee, and any related Collaboration Technology, including Genetic Material(s) relating specifically and solely to such Antibody(ies) and Antibody Cell(s), in each case, and an irrevocable, perpetual, worldwide non-exclusive research license, without the right to sublicense, to make and use, but not to transfer, sell, lease, offer to sell or lease, or otherwise transfer title to or interest in the Collaboration Technology relating specifically and solely to antibody(ies), antibody cell(s) or genetic material(s) having a binding specificity and affinity for such Antigen, in each case, which is necessary for Licensee to make and use the same for research.

License Property
The patents relate to Transgenic non-human animals capable of producing heterologous antibodies.

The Collaboration Know How shall mean, with respect to each Antigen, any parts or derivatives of the Mice prepared by Licensor in connection with the applicable Immunization and delivered to Licensee, including without limitation, Antibody(ies), Antibody Cell(s), polypeptides, Genetic Material(s) or other biological materials derived directly or indirectly from the Mice delivered to Licensee, all information relating specifically and solely to the foregoing, including without limitation, technical data, protocols and methods and processes with respect to Product(s) directed against such Antigen and, all information relating specifically and solely to antibody(ies), antibody cell(s) or genetic material(s) having a binding specificity and affinity for such Antigen, including without limitation, technical data, protocols and methods and processes.

Product(s) shall mean, with respect to an Antigen, a composition or compositions with each composition comprising one or more Antibody(ies), Antibody Cell(s) or Genetic Material(s).

Licensor is the sole and exclusive owner of certain transgenic Mice useful for the preparation of fully human monoclonal antibodies.

HuMAb -Mouse technology is a transgenic mouse system that creates high-affinity, fully human antibodies instead of mouse antibodies.  Using standard, well proven laboratory techniques, scientists can produce these antibodies in a matter of months.

Bispecific antibodies, which enhance and direct the body's own immune system to fight disease; and immunotoxin  technology.

Field of Use
The Field of Use shall mean all uses of Product(s), including all human therapeutic, prophylactic and diagnostic uses of Product(s).

IPSCIO Record ID: 369249

License Grant
Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import Licensed Products solely in the Antibody Targeting Technology Field.

Licensor grants an exclusive, worldwide, license, with the right to sublicense, under the HuMAb Technology and the Licensor Technology to research, develop, make, have made, use, sell, offer for sale and import
— Licensed Royalty-Bearing Products solely in the Antibody Targeting Technology Field, and,
— Anti-Mannose Products.

For Hybridoma Cell Lines; Research License, Licensor grants an exclusive, worldwide license, with the right to sublicense, under the HuMAb Technology to research, make, have made, transfer physical possession of, but not to sell, lease, offer to sell or lease, or otherwise transfer title to, the Hybridoma Cell Lines.

Licensor grants a non-exclusive, worldwide, license, with the right to sublicense, under the Research Patent to conduct research.

For Research Antibodies License, Licensor grants an exclusive, worldwide license, without the right to sublicense, under the HuMAb Technology and the Licensor Technology to use the Research Antibodies for the sole purpose of determining the antigen with respect to which each Research Antibody was raised.

Licensor, who has incorporated Licensee for business opportunities outside of Licensors core business, irrevocably, perpetually and forever assigns and conveys Licensors entire right, title and interest in and to each of the following Assigned Assets
— Antibody Targeting Patents;
— Antibody Targeting Know-How;
— Anti-Mannose Receptor HuMAb Antibodies;
— the Investigational New Drug Application # 11,508 and related governmental filings, and the right to make any future or foreign related filing on –X-1307;
— all quantities of Biological Materials, including those in the possession or control of counterparties to Assigned Contracts;
— all clinical inventories of –X-1307 in the possession or control of Licensor as of the Effective Date; and
— the agreements that are Assigned Contracts.

License Property
Licensor owns or otherwise controls certain technology, including certain patents and know-how, relating to the use of antibodies in connection with the research and development of vaccines.

Anti-Mannose Product shall mean any pharmaceutical composition or formulation incorporating an Anti-Mannose Receptor HuMAb Antibody.

HuMAb Mouse® shall mean any of Licensors immunizable transgenic mice containing unrearranged human immunoglobulin heavy and light chain transgenes, each inserted into mouse chromosomes, but excluding the Additional Mice. HuMAb Mice® shall mean more than one HuMAb Mouse.

The patents relate to Anti-FcyRI (CD64) antibodies.

Field of Use
The field of use is the Antibody Targeting Technology Field.  The Antibody Targeting Technology Field shall mean the use of an antibody, or fragment thereof, whereby the antibody or fragment serves as a targeting means with respect to an Antigen-Presenting Cell for the purpose of modulating an immune response in any of the following manners
—  an antibody or fragment chemically attached or genetically fused to an antigen (including an antigen that is an antibody, or fragment thereof, that encodes an idiotype antigen), whereby the antibody, or fragment thereof, serves as a targeting means for delivering such antigen to an Antigen-Presenting Cell for the purpose of eliciting an immune response,
— an antibody or fragment chemically attached or genetically fused to a toxin or radionuclide, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such toxin or radionuclide to an Antigen-Presenting Cell for the purpose of decreasing, down-regulating or eliminating the activity of such Antigen-Presenting Cell,
— an antibody or fragment chemically attached or genetically fused to a cytokine, adjuvant, or other immuno-modulatory compound, whereby the antibody, or fragment thereof, serves as a targeting means for delivering such compound to an Antigen-Presenting Cell for the purpose of modulating the activity of such Antigen-Presenting Cell, and
— an antibody, or fragment thereof, alone, whereby the antibody or fragment binds to a particular antigen on the surface of an Antigen-Presenting Cell and through such binding modulates the activity of such Antigen-Presenting Cell.

IPSCIO Record ID: 372467

License Grant
University grants the right and license in the territory for the Field of Use to practice under the Patent Rights and, to the extent not prohibited by other patents, to make, have made, use, lease, sell and import Licensed Products and to practice the Licensed Processes, until the expiration of the last to expire of the Patent Rights, unless this Agreement shall be sooner terminated according to the terms hereof.

University grants to an exclusive, royalty-free commercial license to use, reproduce, modify, make derivatives of, and transfer the Tangible Property in conjunction with the Licensed Products and Licensed Processes or as otherwise necessary or useful for the exercise of the Patent Rights licensed hereunder.

University grants to a nonexclusive, non-royalty-bearing license to non-tangible know-how associated with the technology, and further agrees that this know-how may be transferred by Licensee to third parties.

License Property
University is the owner of certain patent rights
—  A Technique For The Treatment Of Human Genetic Disorders of Erythroid Cells;
—  The cDNA of Heme-Regulated Eif-2 Alpha Kinase;
—  Gene Transfer Of A Hybrid (Beta/Delta Or Al ha) Globin Gene, For The Gene Therapy Of Sickle Cell Anemia;
—  Design And Optimization Of Retroviral Vectors Transducing Human Heta-Globin Gene And Locus
Control Region Derivatives;
—  Gene Therapy Procedure Aimed At Inhibition of Tumor Angiogenesis;
—  Integrative Non-Viral Vectors – Based On Retroviral Integrase;
—  Nuclear Transport Of Type-C Retrovirus Based Vectors;
—  LDL Receptor/ Alpha2-Macroglobulin Hybrid Gene;  and,
—  Mutant EEF-2 And 11-3 Hormonotoxin.

University is the co-owner of the Patent Rights for
—  Integrative Non-Viral Vectors (Based on Site-Specific Recombination).

The amendment 1 of December 12, 2003 adds
— Therapeutic Lentiviral Vectors for Gene Therapy of Hemoglobinopathies; and,
— Therapeutic Lentiviral Vectors For Gene Therapy.

Field of Use
Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This process is caused by the release of chemicals by the tumor and by host cells near the tumor.

The hemoglobinopathies are a group of disorders passed down through families (inherited) in which there is abnormal production or structure of the hemoglobin molecule. Sickle cell disease (SCD) is one such blood disorder caused by the abnormal hemoglobin that damages and deforms red blood cells.

Lentivirus is a genus of retroviruses that cause chronic and deadly diseases characterized by long incubation periods, in humans and other mammalian species.

IPSCIO Record ID: 372469

License Grant
The French Licensor, non-profit private foundation dedicated to the study of biology, micro-organisms, diseases, and vaccines, grants a license under the Patents in the Field and in the Territory for research and development, and to manufacture, have manufactured, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import or have imported the Products, to the exclusion of any other rights, which is
—  exclusive for Products containing human (HIV-1 and HIV-2) lentivirus vector, and;
—  non exclusive for Products containing non-human lentivirus vector.
License Property
Licensor has identified and patented a specific nucleotide sequence having a triplex structure, referred to as DNA flap, covered by patents and patent applications.

Ex vivo gene therapy shall mean that cells are extracted from a patient, corrected by placing a healthy or functional gene and transplanted back into patient.

Field of Use
Field shall mean ex vivo gene therapy for human disorders limited to adrenoleukodystophy (ALO) (including but not limited to AMN, CCALD, and all other variants of this disease caused by genetic mutations), beta hemoglobinopathies (including but not limited to betathalassemia and sickle cell anemia), (hemophilia, lysosomal storage disorders (LSDs, including Gaucher disease, Fabry disease, Pompe disease or GAA deficiency, and mucopolysaccharidosis I, II and VI), HIV/AIDS, eye diseases (including but not limited to AMD and Stargardt disease), and Parkinsons Disease; for Parkinsons Disease and eye diseases (including but not limited to AMD and Stargardt disease)].  The Field includes in vivo as well as ex vivo gene therapy.

IPSCIO Record ID: 368653

License Grant
For the options and commercial licenses, the Licensor of Switzerland, an international community of scientists focused on cancer research, grants a Non-exclusive, worldwide license, with rights to grant sub-licenses, under Licensor Patent Rights and Know-How to research, develop, make, have made, use, import, offer for sale, sell and have sold Licensed Products in the Field.
License Property
Licensor owns or has the rights to patents including those relating to Full length Antigens and Part Length Antigens.

Full Length Antigens shall mean the full length protein forms of the Licensor Antigens NY-ES0-1, NY-BR-1 and NY-C0-58.

Part Length Antigens shall mean Polypeptide Sequence forms of the Licensor Antigens MAGE-A3, Melan-A, and SSX2.

Field of Use
Agreement covers potential antigens being studied in non-small-cell-lung, ovarian, and bladder cancers, as well as melanoma.

These antigens, previously identified and characterized immunologically by Licensor , will add to new Licensee development programs for a range of cancer types. NY-ESO-1, MAGE3, and MelanA, in particular, are being studied in non-small-cell-lung, ovarian, and bladder cancers, as well as melanoma in an extended series of Phase I/II programs conducted by the Licensor and its collaborators.

This agreements focus is cancer immunotherapy.

IPSCIO Record ID: 328345

License Grant
Generally, by this collaboration, Licensor shall optimize its Existing AsOR Targeted Complex by construction and improvement of plasmid vectors to obtain the required level and duration of Factor VIlI expression from the recombinant Factor VIlI constructs provided by Licensee.

Licensor grants an exclusive license, or in the case of licensed Third Party Patent Rights or Know-How, when permissible, an exclusive sublicense, in the Territory under Licensors Patent Rights, including Licensors rights in any jointly-owned Patent Rights, and Licensors Know How, to conduct the Collaborative Program and to make, use, sell, offer for sale, import, and have made, used, sold, and imported Products for use in the Hemophilia A Field and to each Additional Field(s) upon Licensees exercise of its option(s).

For the License Grant to Licensee Outside the Field(s), for sole inventions and knowhow made by Licensor during the term of and under the Research Program, which are Improvements in the coding and/or non-coding elements for optimizing and/or regulation of gene expression, Licensor grants a world-wide, non-exclusive,
including the right to grant sublicenses, to practice, make, use, sell, import and have practiced, made, used, sold and imported such Improvements for use outside the Field(s).

License Property
Licensor has certain technology regarding the delivery of human genes for use in the prevention and treatment of diseases, states and conditions in humans.

Alternate Ligand-Targeted Complex shall mean a molecular complex comprising a recombinant AsOR ligand or a non-plasma derived ligand such as, but not limited to, a synthetic carbohydrate ligand, said ligand having the ability to bind to the AsOR receptor and which is covalently linked to a polycation and noncovalently bound to DNA.

AsOR shall mean asialoorosomucoid.

Gene shall mean any one of the Factor VIII Gene or the Additional Gene(s), if any.  Factor VIII Gene shall mean cDNA for full-length human factor VIII or an engineered deletion or substitution constructs, including B-domain deleted constructs, hereinafter modified, of human factor VIII.

Additional Gene shall mean full length or truncated cDNA for a specific human blood coagulation factor, other than factor VIII, which the parties mutually agree to add to the Collaborative Program and the Agreement.

Field of Use
The collaboration agreement is for development gene therapy products for the treatment of hemophilia A, a hereditary blood clotting disorder.

Field shall mean any one of the Hemophilia A Field or the Additional Field(s), if any; or shall mean, collectively, the Hemophilia A Field and the Additional Field(s).

Additional Field shall mean, the treatment of any blood coagulation disorder in humans using Gene Delivery technology for targeting one or more Additional Gene into a mammalian cell of a patient.

IPSCIO Record ID: 246212

License Grant
The Licensor, owned by Licensee's President and a member of the Board of Directors, grants the Licensee an exclusive, worldwide, sub-licensable, royalty-bearing license to the Patent Rights in the Field, including the right to use, market, distribute, make, have made, sell, have sold, offer to sell, import and export Licensed Products and Licensed Services. entitled “In vivo activation of natural killer cells' and to the patents and patent applications. NK cells provide rapid responses to viral-infected cells, and respond to tumor formation.
License Property
Licensor is the owner by assignment of all legal right, title, and interest in the invention entitled  â€œIn vivo activation of natural killer cells'.

Property No. 62/219,652 IN VIVO ACTIVATION OF NATURAL KILLER CELLS

NK cells typically represent approximately 2% to 13% of circulating lymphocytes and are a critical component of the immune system responsible for innate immunity. Unlike adaptive immune cells, they are ever present and ready to attack, having the inherent ability to detect and eliminate diseased cells without the need for antigen presentation, which is why they are called “natural killers.”

Field of Use
The term “Field” or “Field of Use” shall mean all applications of the Patent Rights.  Licensee wishes to acquire the Patent Rights to make, use, sell, offer for sale, and import products, methods, and services.

Licensee, a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer.

IPSCIO Record ID: 380352

License Grant
Licensor grants
— an exclusive license, including the right to sublicense, under the Licensor Patent Rights to make, have made, use, sell, offer for sale and import the Compound, any Research Compound and any Licensed Product in the Field in the Territory,
— an exclusive license, including the right to sublicense, to use Licensor Technology and Licensor Confidential Information to the extent reasonably useful for the manufacture, use, sale, offer for sale and importation of the Compound, any Research Compound and any Licensed Product in the Field in the Territory;

Licensor grants a nonexclusive, worldwide license, including the right to sublicense, under the Licensor Patent Rights in the Field, the Licensor Technology in the Field, and the Licensor Confidential Information, to make, have made, use, sell, offer for sale and import any molecule that is incidental to the manufacture and use of the Compound, any Research Compound, any Licensed Product or any Generic Product.

For the Clinical Development License, Licensor grants an exclusive license, including the right to sublicense, under the Licensor Patent Rights, the Licensor Technology, and the Licensor Confidential Information, to make, have made, use, sell, offer for sale and import the Compound, any Research Compound and any Licensed Product, for any clinical study in the Territory.

For the Research Licenses, without limiting any of the licenses granted, Licensor grants a nonexclusive, irrevocable, worldwide, perpetual license, including the right to sublicense to Affiliates, to use for all research purposes the Licensor Technology disclosed to Licensee during the Term.

License Property
Licensor owns or controls certain patents, patent applications, technology, know-how and technical information relating to immunomodulatory Oligodeoxynucleotides.

Compound means ProMuneâ„¢.

Covered ODNs means any Oligodeoxynucleotide which is claimed generically or specifically in a composition of matter claim in an issued patent owned or controlled by Licensor.

Dermatologic disease means basal cell carcinoma in the skin and squamous cell carcinoma in the skin.

Major indication means First line treatment of breast cancer, second line treatment of breast cancer, first line treatment of NSCLC, first line treatment of colorectal cancer, and with respect to Japan only – first line treatment of non-Hodgkins lymphoma, prostate cancer and gastric cancer.

Licensors Indication means the treatment, Control or prevention of cutaneous T cell lymphoma, including, without limitation, mycosis fungoides.

Field of Use
The field of use includes the treatment, Control or prevention of cancer in humans.

ProMune (CPG 7909) is a toll-like receptor 9 (TLR9) agonist delivered by subcutaneous injection for the potential treatment, control and prevention of cancers in humans.

IPSCIO Record ID: 369334

License Grant
Licensor of England grants a world-wide non-exclusive license under the Intellectual Property to exploit the System make, have made, use, develop, manufacture, market, sell, have sold, offer for sale, distribute, import, and export Product in the Territory.
License Property
The Product means a humanized monoclonal antibody known as Sphingomabâ„¢, which targets sphingosine-1-phosphate (S1P), or an S1P-binding fragment thereof, of which Licensee is the proprietor and which is obtained by the expression of any one gene or of any combination of genes by use of the System.

The System means Licensors glutamine synthetase gene expression system consisting of the Cell Lines, the Vectors, and the System Know-How, whether used individually or in combination with each other.

Field of Use
Licensee has announced the humanization of its Sphingomabâ„¢ monoclonal antibody against sphingosine-1-phosphate (S1P). S1P is an important bioactive lipid that has been well validated as a cancer drug target.

IPSCIO Record ID: 544

License Grant
The parties desire that Licensor, an individual, transfer to Licensee all of Licensor's present and future right, title and interest in and to such intellectual property rights for the consideration and on the terms and conditions set forth in this Agreement, all as described more fully in this Agreement.
License Property
Licensor has independently designed and developed and owns certain intellectual property rights related to two-gene combination cancer vaccines, all as described more fully in this Agreement.

Technology –The term Technology shall mean (a) any United States or foreign patents that claim two-gene combination cancer vaccines and related technology that issue from, or claim priority to, United States patent application serial number 08/838,702 entitled Combination Immunogene Therapy or United States patent application serial number 09/826,025 entitled Combination Immunogene Therapy (or similar name) and related applications including continuations, continuations-in-part, divisional applications and requests for continuing examination (collectively, the Combination Immunogene Therapy Patent Applications).

Field of Use
The combination immunogene therapy technology allows for making a tumor cell more recognizable by the immune system and rendering it susceptible to the cell-killing component of the immune response.

IPSCIO Record ID: 28794

License Grant
Licensor, a non-profit cancer treatment and research institution, granted the Company an exclusive, worldwide License under certain U.S. and foreign patents and patent applications owned or controlled by Licensor, or the Licensor's Patents, to develop, manufacture, use, market, sell, offer to sell, import and export certain products related to the development, manufacture, marketing and sale of therapeutic vaccines for the treatment of various cancers.

Subject to certain limitations, the Company will have the right to subLicense the foregoing rights granted.

Licensor grants an exclusive worldwide right and license under the Patent Rights, including the right to sublicense, to make, offer for sale, import, have made, use, lease and sell Licensed Products and to practice Licensed Processes in the Field of Use.

Licensor grants an exclusive, as it relates to commercial purposes, and not exclusive as it relates to non-commercial purposes, worldwide right and license under the Clinical Data, including the right to sublicense, to make, offer for sale, import, have made, use, lease and sell Licensed Products and to practice the Licensed Processes in the Field of Use.

Licensor grants a non-exclusive worldwide right and license under the Know How, including the right to sublicense, to make, offer for sale, import, have made, use, lease and sell Licensed Products and to practice the Licensed Processes in the Field of Use.

License Property
Licensor is the sole owner of certain Patent Rights and Know How relating to Polyvalent Conjugate Vaccines for Cancer.

The patents include, but are not limited to
Ganglioside-KLH Conjugate Vaccines Plus QS21;
Synthetic Compounds Which Bind To H. Pylori And Uses Thereof;
Alpha-O-Linked Glycycoconjugates with Clustered (2,6)-ST Epitopes, Methods of Preparation and Uses Thereof; and,
Polyvalent Conjugate Vaccine for Cancer.

Field of Use
The Field of Use shall mean monovalent and multi-molecular polyvalent cancer vaccines, except that, for the Globo H antigen, Field of Use shall mean multi-molecular polyvalent cancer vaccines. Multi-molecular polyvalent cancer vaccine means a cancer vaccine containing more that one type of antigen but not in the same molecule.

IPSCIO Record ID: 356265

License Grant
The Parties collaborate together to research, develop and commercialize therapeutic products in the Field and Licensee will have the exclusive option to take a license to each Product Candidate, whereby Licensor hereby grants to Licensee a worldwide, exclusive (even as to Licensor) license, with the right to sublicense, under Licensed IP, to Develop Elected Candidate and to Develop and Commercialize Licensed Product.
License Property
Licensor patents
US 5,464,758 – Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US 5,589,362 – Tetracycline regulated transcriptional modulators with altered DNA binding specificities
US 5,654,168 – Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units

CAR T-cell therapy represents a promising, emerging approach to treating cancer. Blood is withdrawn from a patient and the T-cells are then extracted from a patient's blood. These cells are then genetically modified to recognize and attack cancer cells and then re-introduced into the patient's blood. The patient’s genetically modified cells are intended to bind to and kill the target cancer cells.

Field of Use
The  broad, global strategic collaboration is to discover, develop and commercialize novel diseasealtering gene therapies in oncology.

The collaboration will focus on applying gene therapy technology to genetically modify a patient’s own T-cells, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells.

Field means the use of (i) T-Cells expressing a CAR (with or without other engineering to enhance functionality and/or safety), including virus specific genetically modified T-Cells expressing a synthetic CAR, and (ii) T-Cells expressing native-virus antigen receptors or tumor-specific antigen receptors in which the T-Cells are genetically modified to enhance their performance, persistence or safety, in each case under (i) and (ii) for the treatment, modulation, palliation or prevention of cancer in humans.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.